NeuroVigil

Executive Summary

NeuroVigil is a San Diego-based neurotechnology company founded in 2007 that has developed iBrain, an AI-powered, non-invasive brain monitoring platform. The platform analyzes electroencephalography (EEG) data to assess sleep quality, diagnose neurological disorders such as Parkinson's and Alzheimer's, and accelerate drug development for central nervous system (CNS) conditions. By eliminating the need for invasive procedures or bulky equipment, NeuroVigil aims to make brain health monitoring accessible and scalable. The company's technology leverages machine learning algorithms to extract actionable biomarkers from brain activity, positioning it as a leader in digital neuroscience. Despite operating in a competitive landscape with players like Muse and NeuroSky, NeuroVigil differentiates through clinical-grade accuracy and a focus on regulatory and pharmaceutical applications. With 15+ years of research and development, the company has amassed a robust intellectual property portfolio. However, as a private company, NeuroVigil's financials and commercialization progress are not publicly disclosed. The digital health market for neurological diagnostics is projected to grow significantly, driven by an aging population and rising prevalence of neurological disorders. NeuroVigil is well-positioned to capitalize on this trend, provided it can secure regulatory approvals and strategic partnerships. The company's non-invasive approach addresses a key unmet need for objective, home-based neurological monitoring, which could reduce healthcare costs and improve patient outcomes.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for iBrain in sleep apnea diagnostic aid70% success
• H2 2026Partnership with a top-10 pharmaceutical company for CNS drug trial monitoring60% success